- March 13, 2013
-- Thomas McLain Appointed as President and Chief Executive Officer for Vermillion, Inc.
Austin, TX, March 18, 2013 —
SANFORD ROSE ASSOCIATES® – SAN DIEGO, (www.sanfordrose.com/
sandiego) an executive search firm specialized in building management teams for personalized medicine, cardiology, oncology and women’s health companies, announces the placement of Thomas McLain as President and Chief Executive Officer for Vermillion, Inc., located in Austin, TX.
Mr. McLain recently served as both CEO and CFO of Claro Scientific, LLC, an innovative early stage diagnostic company, bringing commercial focus to the development and implementation of a broad platform technology and clinical study program. Mr. McLain developed a favorable convertible note program to raise $4 million from private investors for early financing. He also directed development of a licensing and strategic partnering program to generate non-dilutive funding and operating cash flow. Prior to joining Claro, he was the Chairman, Chief Executive Officer, and President of Nabi Biopharmaceuticals (http://www.nabi.com/
), increasing the company's market capitalization from $175 million to over $1 billion within three years. Prior to this Mr. McLain was employed by Bausch & Lomb, Inc. (http://www.bausch.com/en_US/default.aspx
), a global eye care company, where he developed the business case and led a worldwide team to execute an initiative to reduce operating costs and improve gross margins which delivered a significant positive return on investment in terms of earnings and cash savings, as well as operational efficiencies. He also led the implementation of three significant treasury transactions that delivered more than $500 million in value. Before joining Bausch & Lomb, Mr. McLain practiced with the accounting firm of Ernst & Young, LLP (http://www.ey.com/
Mr. McLain is the former director of Eastman Chemical Company (http://www.eastman.com/
serving as a member of the Board of Directors, the Audit and Finance Committees and as Chair of the Health, Safety, Environment and Security (HSES) Committee. He is the past Chairman of BioFlorida (http://www.bioflorida.com/)
and remains on the advisory committee of the statewide trade association for the bioscience industry. Mr. McLain has also served as a member of the board of BIO (http://www.bio.org/)
. Mr. McLain holds an MBA in Accounting/Information Systems from the University of Rochester, Simon Graduate School of Business and a BA in economics from the College of the Holy Cross.
Robin Toft, President and Chief Executive Officer of Sanford Rose Associates® – San Diego said, “We are very proud to have partnered with Vermillion on this significant search and to have placed Mr. McLain into the prestigious position of President and Chief Executive Officer. Mr. McLain is a dynamic leader with 15 years experience as a President and CEO of both publicly traded and privately held venture growth companies focused on laboratory services, biopharmaceutical, biotechnology and healthcare services. He will be a valuable asset as Vermillion focuses on their global commercialization efforts. We believe that Mr. McLain’s experience will be crucial as the company develops and commercializes their diagnostic tests to be recognized as the leader in the advancement of women’s health.”
Sanford Rose Associates® - San Diego (www.sanfordrose.com/
sandiego) is committed to filling mid to executive-level management positions exclusively in biotechnology, medical device, diagnostic, pharmaceutical and healthcare companies. Sanford Rose Associates® - San Diego is the top performing Life Sciences focused executive search firm within the global Sanford Rose Associates® network, which has 60 offices worldwide and is a member of the International Executive Search Federation (IESF). We can help bring “A-players”
to your organization-
please contact President and CEO, Robin Toft at 858-546-4801 email@example.com.